Study of zanubrutinib in Waldenström macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Waldenström macroglobulinemia (WM)
- Your blood test shows IgM (an antibody) is higher than 0.5 g/dL
- You are starting, already taking, or plan to take zanubrutinib for WM
- Your bone marrow test shows a specific MYD88 result (either MYD88 L265P or a non-L265P/MYD88WT type)
- There is no evidence that your WM has changed into a different, more aggressive cancer before starting zanubrutinib
- You do not have another non-Hodgkin lymphoma type, and you are not in another treatment trial while on zanubrutinib
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies zanubrutinib combined with BR (bendamustine and rituximab) in adults newly diagnosed with Waldenström macroglobulinemia (WM) who have symptoms. It may help shrink the abnormal disease and improve symptoms like high blood stickiness, nerve problems, anemia, and other lymphoma-related issues.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests a combination of two targeted drugs, zanubrutinib and BGB-11417, for people with Waldenström Macroglobulinemia who have already had at least one prior treatment. The goal is to see if this two-drug approach works better than standard options.
This trial tests a combination of two drugs—mosunetuzumab and pirtobrutinib—in patients whose Waldenstrom macroglobulinemia (a rare blood cancer) has returned or stopped responding to prior treatment. The study aims to see if this combination can shrink tumors and help patients feel better.
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.